Partner's Blog - March 2019

 

View all updates

The Corporate Affiliates Program provides an exciting opportunity for companies to support the work of the American Society of Transplantation (AST) and receive tangible benefits throughout the year. The following companies are members of the 2019 Corporate Affiliate Program (CAP):

What's News With Our Partners:

  • Join us at ATC for an educational Lunch Symposium, Better Transplant Outcomes Start with Better Surveillance, Tuesday, June 4th from 1-2: 15 pm in the Grand Ballroom, Sheraton Boston Hotel, to learn more about the value of AlloSure for you and your patients!

  • MEDEOR THERAPEUTICS is a clinical-stage biotechnology company dedicated to discovery, development and commercialization of personalized cellular immunotherapies to improve outcomes in organ transplant recipients and patients that suffer from hematologic conditions. Our team of professionals possess deep expertise in hematology, cellular immunotherapy, and transplantation product development. Medeor's product candidates each comprise a unique composition of different types of hematopoietic donor-derived cells, based on breakthrough technologies discovered at Stanford University and exclusively licensed by Medeor. These product candidates are designed to produce mixed chimerism, the co-existence of both recipient and donor blood and immune cells in the recipient. For organ transplant patients, mixed chimerism achieves donor-specific immune tolerance, which reduces the likelihood of transplant organ loss, reduces or eliminates chronic immunosuppressive drug therapy, and thereby improves patient outcomes. For hematologic conditions, mixed chimerism has the potential to reduce or eliminate disease symptoms. Our pipeline addresses critical medical needs of the approximately 130,000 annual organ transplant recipients worldwide as well as patients who suffer from serious hematologic conditions. Medeor is located in South San Francisco, California.

 

​​

  • Two-Year Results of Phase 3, Double-Blind, Randomized Trial in De Novo Kidney Transplant Patients Veloxis Pharmaceuticals. Read More

 

Check out all of our CAP partners: